Ferring Launches New Treatment of Advanced Prostate Cancer in Europe
Firmagon (degarelix), a new treatment option in hormonal therapy for prostate cancer, has been presented by Ferring at the 24th Annual European Association of Urology (EAU) Congress in Stockholm, Sweden.
Firmagon is a new GnRH receptor blocker indicated for the treatment of patients with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from commonly used hormonal therapies.
- This is an important new step for the treatment of advanced, hormone-dependent prostate cancer, with Firmagon offering a new option and hope for many patients, says John Anderson, Consultant Urological Surgeon, The Royal Hallamshire Hospital, Sheffield, United Kingdom.
The European launch of Firmagon follows the decision of the European Commission to grant marketing authorisation in the European Union last month. This approval was based on pivotal Phase III studies where Firmagon produced a reduction in levels of testosterone 1,2 below 0.5ng/ml within three days in more than 96% of study patients.
Firmagon will be marketed in Europe by Ferring Pharmaceuticals.
Read more here
